| 主权项 |
1. A method for treating, delaying onset, reducing the incidence of, or reducing the severity of a fibrosis in a subject, comprising administering a compound, or its optical isomer, pharmaceutically acceptable salt, pharmaceutical product, N-oxide, hydrate or any combination thereof, represented by the structure of Formula XI:Wherein R1, R2, and R3 are each, independently, hydrogen, aldehyde, COOH, —C(═NH)—OH, CHNOH, CH═CHCO2H, CH═CHCO2R, —CH═CH2, hydroxyalkyl, halogen, hydroxyl, alkoxy, cyano, nitro, CF3, NH2, 4-methoxyphenyl, 4-hydroxyphenyl, SH, COR, COOR, OCOR, alkenyl, allyl, 2-methylallyl, alkynyl, propargyl, OSO2CF3, OSO2CH3, NHR, NHCOR, N(R)2, sulfonamide, SO2R, alkyl, cycloalkyl, haloalkyl, aryl, phenyl, benzyl, protected hydroxyl, OCH2CH2NR4R5, Z-Alk-Q, Z-Alk-NR4R5, Z-Alk-heterocycle or OCH2CH2-heterocycle in which the heterocycle is a 3-7 membered saturated or unsaturated, substituted or unsubstituted heterocyclic ring;
R is alkyl, cycloalkyl, hydrogen, haloalkyl, dihaloalkyl, trihaloalkyl, CH2F, CHF2, CF3, CF2CF3, aryl, phenyl, benzyl, -Ph-CF3, -Ph-CH2F, -Ph-CHF2, -Ph-CF2CF3, halogen, alkenyl, CN, NO2 or OH; R′ is hydrogen, Alk or COR; R″ is hydrogen, Alk or COR; R4 and R5 are independently hydrogen, phenyl, benzyl, an alkyl group of 1 to 6 carbon atoms, a 3 to 7 member cycloalkyl, heterocycloalkyl, aryl or heteroaryl group; Z is O, NH, CH2 or Q is SO3H, CO2H, CO2R, NO2, tetrazole, SO2NH2 or SO2NHR; h is 0, 1, 2 or 3; i is 0, 1, 2, 3 or 4; n is 1, 2, 3 or 4; m is 1 or 2; p is 0, 1, 2, 3, 4 or 5; and Alk is a linear alkyl of 1-7 carbons, branched alkyl of 1-7 carbons, or cycloalkyl of 3-8 carbons. |
